Description
Retatrutide 30 mg Research Peptide
Retatrutide 30 mg, also known by the development code LY3437943, is an investigational synthetic peptide supplied in lyophilized powder form for qualified laboratory and scientific research. Retatrutide is studied as a triple receptor agonist because a single peptide molecule demonstrates agonist activity at the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) . This multi-receptor profile makes the compound relevant to research involving incretin signalling, receptor pharmacology, metabolic pathways and the development of multi-agonist peptides.
Each vial contains 30 mg of Retatrutide research peptide in lyophilized form. The 30 mg value identifies the total stated vial content and must not be interpreted as a clinical dose, treatment recommendation or instruction for self-administration. This product is supplied exclusively for laboratory, analytical and scientific applications and is not intended for human or veterinary use.
What Is Retatrutide (LY3437943)?
Retatrutide is a long-acting research peptide designed to combine activity at three metabolically relevant receptor systems within one molecule. Published scientific literature identifies LY3437943 as an agonist at the GIP, GLP-1 and glucagon receptors . This coordinated triple-agonist design distinguishes Retatrutide from research compounds that target only GLP-1R or the combined GIPR and GLP-1R pathways.
The compound has attracted scientific interest because multi-receptor agonism provides a framework for studying how several signalling pathways may interact. Rather than examining a single receptor in isolation, researchers can investigate the combined pharmacological profile of GIPR, GLP-1R and GCGR activity within the same peptide structure. Retatrutide remains an investigational compound and has not been approved as a medicinal product .
Triple-Receptor Agonist Profile
The defining characteristic of Retatrutide is its activity across three receptor targets. Each receptor forms part of a broader network of metabolic and endocrine signalling, while the combined profile supports research into coordinated receptor activation.
GIP receptor activity: The glucose-dependent insulinotropic polypeptide receptor is studied within incretin biology, nutrient signalling and metabolic regulation. Retatrutide includes GIPR agonist activity as one component of its triple-receptor design.
GLP-1 receptor activity: The glucagon-like peptide-1 receptor is a widely investigated target in incretin and metabolic research. Retatrutide incorporates GLP-1R agonism within the same molecular structure rather than using it as a standalone receptor pathway.
Glucagon receptor activity: The glucagon receptor represents the third component of the Retatrutide receptor profile. Its inclusion allows researchers to examine GCGR activity alongside GIPR and GLP-1R signalling within a single multi-agonist research compound.
Together, these three targets define Retatrutide as a GIP, GLP-1 and glucagon receptor agonist peptide. The term “triple receptor agonist” is the scientifically appropriate description of this research profile.
Retatrutide Research and Development Context
Retatrutide has been evaluated in published clinical research under the development code LY3437943. Scientific studies have examined its pharmacology, pharmacokinetic profile, receptor activity, safety and effects within controlled clinical-trial environments . Information from these studies is relevant for compound identification and scientific context, but it must not be used as a self-administration guide or interpreted as evidence that commercially available research material is suitable for medical use.
Clinical-trial protocols involve pharmaceutical-grade investigational material, controlled manufacturing, professional medical supervision and defined eligibility criteria. A laboratory research vial offered by an independent supplier must not be presented as equivalent to clinical-trial material or as an approved pharmaceutical product. Any discussion of published research should therefore remain educational and should not include consumer dosing, treatment instructions or guaranteed outcomes.
Product Specifications
Compound name: Retatrutide
Development code: LY3437943
Vial content: 30 mg
Physical form: Lyophilized powder
Compound class: Investigational triple receptor agonist peptide
Research targets: GIPR, GLP-1R and GCGR
Product category: Metabolic research peptide
Intended application: Laboratory, analytical and scientific research
Purity: Refer to the batch-specific Certificate of Analysis
Use restriction: Not for human or veterinary use
Lyophilized Retatrutide 30 mg Format
Lyophilization converts the research material into a dry powder format suitable for controlled laboratory storage and handling under the conditions specified in the batch documentation. The vial should remain clearly identified with the compound name, stated content and batch information to support inventory control and traceability.
Researchers should consult the batch-specific Certificate of Analysis (COA) before beginning analytical work. The documentation should correspond to the exact Retatrutide 30 mg product and batch supplied. Relevant records may include the sample or batch number, analytical method, test date and measured result. Purity or independent-testing claims should only be used when supported by documentation for the same batch.
Laboratory Research Applications
Retatrutide 30 mg may be relevant to qualified research projects involving multi-receptor agonist design, comparative peptide analysis, receptor-binding studies, analytical method development, incretin signalling and metabolic pathway research. The compound may also serve as a reference material in appropriately designed laboratory investigations where its identity and batch characteristics have been independently evaluated.
The suitability of the product for a particular experiment must be determined by the responsible researcher. Experimental design, preparation methods, concentrations, controls and analytical procedures should follow validated institutional protocols. This product page does not provide a preparation protocol, reconstitution guide, clinical dosage or instructions for biological administration.
Quality, Traceability and Batch Documentation
Reliable research depends on clear product identity and batch traceability. Before use, verify that the vial label and accompanying documentation identify Retatrutide, LY3437943, the stated 30 mg vial content and the relevant batch or sample number. Where a Certificate of Analysis or independent laboratory report is available, retain it with the experimental records.
Batch documentation is especially important for research peptides because specifications can vary between suppliers and production batches. No analytical result should be assumed to apply to a different vial, batch, concentration or manufacturer. Researchers should independently determine whether the supplied material meets the requirements of their planned work.
Storage and Handling
Store the unopened Retatrutide 30 mg vial under the conditions stated in the product and batch documentation. Keep the material securely sealed and protected from contamination, moisture, excessive heat and direct light. Access should be restricted to trained laboratory personnel familiar with the applicable handling procedures.
Use suitable personal protective equipment and follow institutional safety, documentation and disposal requirements. Do not use the material if the vial, label or protective packaging is damaged, inconsistent or missing essential identification information.
Research Use Only
Retatrutide 30 mg is supplied exclusively for laboratory, analytical and scientific research. It is not intended for human consumption, self-administration, veterinary use, diagnostic procedures or therapeutic application. Retatrutide remains investigational and is not an approved medicine. Product information and references to published studies are provided solely for compound identification and educational context. They do not constitute medical advice, a dosing recommendation or instructions for use.
Scientific References
[1] Coskun et al. — LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist
[2] Jastreboff et al. — Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
[3] Eli Lilly — What to know about retatrutide